|
AU2018317153A1
|
|
Fgfr inhibitor and medical application thereof
|
|
AU2018213637A1
|
|
LSD1 inhibitor and preparation method and application thereof
|
|
CN103690968A
|
|
Voriconazole composition and preparation method thereof
|
|
CN103319422A
|
|
New gefitinib crystal form and preparation method thereof
|
|
CN103142509A
|
|
Bortezomib pharmaceutic composition for injection
|
|
CN103113210A
|
|
Hydroxyl amyl benzoate potassium crystal and preparation method thereof
|
|
CN103893151A
|
|
Venlafaxine hydrochloride sustained release capsule and preparation method thereof
|
|
CN103898146A
|
|
Method for preparing recombined human vascular endothelial cell growth factor A
|
|
CN103897008A
|
|
Method for preparing decitabine and intermediate thereof
|
|
CN103893139A
|
|
Asenapine composition and preparation method thereof
|
|
CN103181904A
|
|
Ertapenem sodium freeze-dried preparation and preparation method thereof
|
|
CN103833590A
|
|
Tigecycline crystal form and preparation method thereof
|
|
CN103830200A
|
|
Composition of 3-n-butylphthalide derivative, and preparation method thereof
|
|
CN103784424A
|
|
Butylphthalide transdermal patch and preparation method thereof
|
|
CN103709156A
|
|
Dasatinib polymorph medicine and preparation method thereof
|
|
CN103027300A
|
|
VE (Vitamin E) coenzyme Q10 composition for assisting to reduce blood fat and boosting immunity and preparation method thereof
|
|
CN102988279A
|
|
Pinocembrin and cyclodextrin supermolecular inclusion complex and preparation method thereof
|
|
CN103664929A
|
|
Dasatinib polycrystalline form medicament and preparation method thereof
|
|
CN103626735A
|
|
Duloxetine hydrochloride crystal form and preparation method thereof
|
|
CN102824371A
|
|
Propolis-lycopene composition and preparation method thereof
|
